Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study-Reference-Cited by-同舟云学术

Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study

Published:2020-08-03 Issue:2 Volume:31 Page:394-398
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Chen Hua¹²^ORCID,Qi Xuan¹²,Li Yuan¹²,Wu Qing³,Shi Qun¹²,Wang Li¹²,Li Jing¹²,Zhao Lidan¹²,Zhang Li¹²,Zhou Xinyao⁴,Fei Yunyun¹²,Liu Jinjing¹²,Su Jinmei¹²,Wu Di¹²,Yang Yunjiao¹²,Jiang Hui¹²,Zeng Xiaofeng¹²,Zhang Fengchun¹²,Zhao Yan¹²

Affiliation:

1. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

2. Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China

3. Department of Stomatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

4. Department of Rheumatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2020.1789335

Reference15 articles.

1. Sjögren's syndrome

2. Treatment of primary Sjögren syndrome

3. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23

4. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome

5. Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iguratimod Alleviates Experimental Sjögren’s Syndrome by Inhibiting NLRP3 Inflammasome Activation;Cell Biochemistry and Biophysics;2024-06-05

2. Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction;Journal of Pharmaceutical and Biomedical Analysis;2024-06

3. Zielgerichtete Immuntherapien beim primären Sjögren-Syndrom;Arthritis und Rheuma;2024-04

4. Update zum Sjögren-Syndrom: Diagnostik & Therapie;Aktuelle Rheumatologie;2024-03-05

5. Effects of iguratimod on inflammatory factors and apoptosis of submandibular gland epithelial cells in NOD mice;Scientific Reports;2023-10-24